Cancer Research

Can Nanocarriers Overcome Resistance in Head and Neck Cancer?
Research & Development Can Nanocarriers Overcome Resistance in Head and Neck Cancer?

Bioinformatics analyses have identified the kinase DYRK1A as a critical upstream regulator that maintains tumor growth even when standard signaling pathways are pharmacologically blocked. From 2026 to 2030, the global incidence of head and neck squamous cell carcinoma (HNSCC) is expected to grow by

Can Deep Learning Predict Ki-67 Levels in Breast Cancer?
Tech & Innovation Can Deep Learning Predict Ki-67 Levels in Breast Cancer?

Transformer models utilize self-attention mechanisms to weigh the importance of different tumor regions, capturing global structural context better than traditional convolutional networks. In the current medical landscape of 2026, the convergence of oncology and artificial intelligence has yielded

Why Do Cancer Drugs Targeting the Wee1 Protein Fail?
Research & Development Why Do Cancer Drugs Targeting the Wee1 Protein Fail?

Researchers have identified that inhibiting the Wee1 protein inadvertently disables a critical switch required for all fast-proliferating cells to begin the DNA replication process. For decades, the pharmaceutical industry has focused on Wee1 as a potential vulnerability for tumors that lack the

AI and Nanotech Transform Lung Cancer Mutation Detection
Tech & Innovation AI and Nanotech Transform Lung Cancer Mutation Detection

Current research into the long-term biological safety of nanoparticles is essential to address concerns regarding oxidative stress and potential cytotoxicity in human patients. This investigation is particularly vital as the medical and scientific community pivots toward the intersection of

Is STING the Key to Treating Triple-Negative Breast Cancer?
Research & Development Is STING the Key to Treating Triple-Negative Breast Cancer?

The aggressive nature of triple-negative breast cancer often leaves clinicians with a narrow window for effective intervention due to its lack of hormone receptors and rapid metastatic progression. This specific subtype has historically bypassed traditional targeted therapies, necessitating a

Study Links MAGE-A4 Levels and Tumor Burden to Afami-Cel Success
Research & Development Study Links MAGE-A4 Levels and Tumor Burden to Afami-Cel Success

The biological hurdles of treating solid tumors with T-cell therapy are being decoded through new findings linking tumor lesion diameters to the ultimate durability of the patient response. At the current Society for Immunotherapy of Cancer Annual Meeting, researchers presented updated data

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later